Like many other cancers, dysregulated kinase activity is a main feature driving AML oncogenic signaling, with the most common mutations seen at diagnosis in the receptor tyrosine kinase FLT3 (20–35% patients) [35, 36]. This evidence concerns the gene NTRK1 and cancer.